

# HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells

Akira Hirata,<sup>1,2</sup> Fumihito Hosoi,<sup>3</sup> Miho Miyagawa,<sup>1</sup> Shu-ichi Ueda,<sup>1</sup> Seiji Naito,<sup>2</sup> Teruhiko Fujii,<sup>3</sup> Michihiko Kuwano,<sup>3</sup> and Mayumi Ono<sup>1</sup>

Departments of <sup>1</sup>Medical Biochemistry and <sup>2</sup>Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka; and <sup>3</sup>Research Center for Innovative Cancer Therapy for Medical Science, Kurume University, Kurume, Japan

## Abstract

Gefitinib (Iressa), an epidermal growth factor receptor targeting drug, has been clinically useful for the treatment of patients with non-small cell lung cancer (NSCLC). Gefitinib is currently being applied in clinical studies as either a monotherapy, or as part of a combination therapy against prostate, head and neck, gastric, breast, and colorectal tumors. However, success rates vary between different tumor types, and thus it is important to understand which molecular target(s) are responsible for limiting the therapeutic efficacy of the drug. In this study, we ask whether expression of HER2 affects sensitivity to gefitinib in human lung cancer cells. We established two clones, LK2/HER2-32 and LK2/HER2-57, by transfecting HER2 cDNA into LK2, a NSCLC line with a low expression level of HER2. We observed no mutations in exons 18, 19, and 21 of EGFR gene in LK2, LK2/mock- and two HER2-transfectants when we observed in-frame deletion mutations (E746-A750) adjacent to K745 in a gefitinib-sensitive NSCLC cell line, PC9. These LK2/HER2-32 and LK2/HER2-57 were much more sensitive to the cytotoxic effects of gefitinib than the parental LK2 lines. Treatment with 0.5 to 1  $\mu\text{mol/L}$  gefitinib specifically blocked Akt activation in both HER2-transfectant lines, but not in the parental LK2 cells. Extracellular signal-regulated kinase-1/2 activation, however, was not blocked by gefitinib up to 10  $\mu\text{mol/L}$  in either the parent or transfectant lines. Gefitinib was also shown to induce cell cycle arrest in the G<sub>1</sub>-S phase, and an accompanying increase of p27<sup>Kip1</sup> was observed. LK2/HER2 transfectants showed constitutive formation of HER2/HER3 heterodimer, which were seen to associate with a regulatory subunit of phosphoinositide-3-kinase, p85 $\alpha$ , when active. Treatment of LK2/HER2 cells with gefitinib markedly decreased the formation of HER2/HER3 heterodimers, HER3 basal phosphorylation, and the association of p85 $\alpha$  with HER3. This study is the first to show that under basal growth conditions, HER2 sensitizes low-EGFR NSCLC cell lines to growth inhibition by gefitinib. (Cancer Res 2005; 65(10): 4253-60)

## Introduction

The epidermal growth factor receptor (EGFR) family (EGFR/HER1/erbB1, HER2/neu, HER3/erbB3, and HER4/erbB4) operates a complex signal transduction cascade through phosphoinositide-3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK)1/2, and modulates proliferation, migration, adhesion, differentiation, angiogenesis, and apoptosis of cancer cells (1–3). Overexpression of EGFR is often associated with advanced tumor stages, metastasis, and poor clinical outcome of several human malignant tumors such as non-small cell lung cancer (NSCLC), and cancers of breast, cervix, head and neck, esophagus, and colorectum (4–7). During the last decade, the EGFR family has been targeted in order to develop novel anticancer drugs in the form of small molecules or monoclonal antibodies (8–10).

Gefitinib (Iressa, ZD1839) is an orally active, selective EGFR tyrosine kinase inhibitor that blocks the signal transduction pathway implicated in cancer growth (11, 12). It has antiproliferative activity in various human cancer cell types *in vivo* as well as *in vitro* (13, 14). Clinically significant antitumor activity was observed in two phase II trials of gefitinib monotherapy in pretreated patients with advanced NSCLC (IDEAL 1 and 2), and gefitinib is now approved in several countries including Japan, Australia, and the U.S. for the treatment of advanced NSCLC (15, 16). Extensive clinical testing, using gefitinib as a monotherapy or as part of a combination therapy, has enabled a number of treatments to be developed against prostate, head and neck, gastric, breast, and colorectal cancers (17). Gefitinib is a promising agent for the treatment of a wide range of tumor types and shows improved therapeutic efficacy when combined with radiation or chemotherapy in various cell lines and xenografts (13, 14, 18–20).

A recent highlight is the novel finding of intrinsic importance that a subgroup of patients with NSCLC has specific mutations in the EGFR genes are well correlated with clinical responsiveness to gefitinib (21). These EGFR mutations lead to increased growth factor signaling and confer susceptibility to gefitinib. Another relevant study by Paez et al. (22) has also reported that somatic mutations of the EGFR gene in 15 of 58 unselected NSCLC tumors from Japan and 1 of 61 from the U.S., and treatment with gefitinib was found to cause tumor regression in NSCLC patients more frequently in Japan than in the U.S. Screening for such mutations in the EGFR gene in NSCLC may identify patients who will have a responsiveness to gefitinib (21, 23). Moreover, we have recently observed that susceptibility to gefitinib is closely correlated with EGFR-dependent Akt and ERK1/2 activation levels among nine NSCLC cell lines under basal growth conditions (23). Consistent with this study (23), treatment with a

Note: "Iressa" is a trademark of the AstraZeneca group of companies.

Requests for reprints: Mayumi Ono, Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Phone: 81-92-642-6098; Fax: 81-92-642-6203; E-mail: ahirata@uro.med.kyushu-u.ac.jp.

©2005 American Association for Cancer Research.

very low dose of gefitinib of the drug-sensitive NSCLC cell line with EGFR mutations resulted in almost complete inhibition of EGFR autophosphorylation and the phosphorylation of its downstream targets, ERK1/2 and Akt (22).

On the other hand, overexpression of HER2 in various cancer cell lines or xenografts increases cytotoxicity and/or the antitumor effects of gefitinib (24–27). HER2/erbB2, a 185 kDa transmembrane protein tyrosine kinase, is overexpressed by gene amplification and constitutively activates cancer cell proliferation (28). Amplification of the HER2 gene has been reported in several types of cancer including breast, ovarian, stomach (29, 30), and NSCLC (31, 32), and most of these cases have been associated with poor prognosis (33–35). Of the HER family proteins, gefitinib inhibits EGFR/HER1 phosphorylation with an  $IC_{50}$  of 27 to 33 nmol/L and HER2 phosphorylation with an  $IC_{50}$  of 3.7  $\mu$ mol/L, suggesting about 100-fold difference in the drug sensitivity for EGFR and HER2 (11). HER3 is deficient in the tyrosine kinase domain and therefore shows no affinity to gefitinib. Because no studies seem to have addressed how HER2 overexpression modulates sensitivity to gefitinib in human cancer cells, we established isogenic cell lines with or without HER2 overexpression, in order to determine the mechanism of HER2 action. We have recently observed that one NSCLC cell line, LK2, expresses little, if any, EGFR and HER2, but moderately expresses HER3 (23). In our present study, we have established two sublines of LK2 (LK2/HER2) that have been transfected with wild-type HER2 cDNA, and we have examined how drug sensitivity to gefitinib is differentially controlled between LK2 and LK2/HER2.

## Materials and Methods

**Materials.** The following materials were obtained from the indicated sources: Gefitinib (AstraZeneca, Macclesfield, United Kingdom); anti-HER2, anti-HER3, anti-p85 $\alpha$ , and anti-phospho-HER2 antibodies (Upstate Biotechnology, Lake Placid, NY); antibodies to ERK1/2, phospho-ERK1/2, Akt, phospho-Akt and p21<sup>WAF1/CIP1</sup> (Cell Signaling Technology, Beverly, MA); anti-P-Tyr antibody (Santa Cruz Biotechnology, Santa Cruz, CA); anti- $\beta$ -actin antibody, propidium iodide and RNase A (Sigma, St. Louis, MO); anti p27<sup>Kip1</sup> antibody (BD Transduction Laboratories, San Jose, CA); anti-HER3 antibody for immunoprecipitation (NeoMarkers, Montreal, Quebec, Canada).

**Cell culture.** LK2 cells were purchased from Japanese Collection of Research Bioresources (Tokyo, Japan), PC9 and QG56 cells were kindly provided from Dr. Yukito Ichinose (Kyushu Cancer Center, Fukuoka, Japan). These cells were cultured in RPMI supplemented with 10% fetal bovine serum (23). LK2/HER2-32 and LK2/HER2-57 cells were established after stable transfection with pIRESHyg2 expression plasmids (Clontech Laboratories, Palo Alto, CA) using Lipofectin 2000 Reagent (Invitrogen, San Diego, CA). These cells were cultured in RPMI supplemented with 10% fetal bovine serum and 350  $\mu$ g/mL hygromycin, and were maintained under standard cell culture conditions at 37°C and 5% CO<sub>2</sub> in a humid environment.

**Cell growth assay.** Cell growth curves were determined by plating 5  $\times$  10<sup>3</sup> cells in a 24-well plate. After 24 hours, 20 ng/mL of EGF or vehicle was added, followed by incubation at 37°C. The medium was replaced every other day with fresh medium containing either EGF or vehicle, and cells were counted by a Coulter counter at indicated times.

**Western blot and immunoprecipitation.** Subconfluent tumor cells cultured in medium supplemented with 10% fetal bovine serum were incubated with various concentrations of gefitinib for 3 hours at 37°C. The cells were then rinsed with ice-cold PBS and lysed in Triton X-100 buffer (50 mmol/L HEPES, 150 mmol/L NaCl, 1% Triton X-100, and 10% glycerol containing 1 mmol/L phenylmethylsulfonyl fluoride, 10  $\mu$ g/mL aprotinin, 10  $\mu$ g/mL leupeptin, and 1 mmol/L sodium vanadate), and cell lysates were subjected to SDS-PAGE and transferred to Immobilon membranes (Millipore, Bedford, MA) as described previously (23, 36). After transfer,

blots were incubated with the blocking solution and probed with anti-HER2 antibody, anti-HER3 antibody, anti-p85 $\alpha$  antibody, anti- $\beta$ -actin antibody, anti-phospho-HER2 antibody, anti-ERK1/2 antibody, anti-phospho-ERK1/2 antibody, anti-Akt antibody, anti-phospho-Akt antibody, anti-p21 antibody, or anti-p27 antibody followed by washing. The protein content was visualized using horseradish peroxidase-conjugated secondary antibodies followed by enhanced chemiluminescence (Amersham, Piscataway, NJ). For immunoprecipitation, 4 mg of total protein from cell lysates using NP40 buffer (50 mmol/L Tris-HCl, 1 mmol/L EDTA, 80 mmol/L NaCl, 0.3% NP40, and 10% glycerol containing 1 mmol/L phenylmethylsulfonyl fluoride, 10  $\mu$ g/mL aprotinin, 10  $\mu$ g/mL leupeptin, and 1 mmol/L sodium vanadate) was incubated for 2 hours with anti-HER3 antibody and Protein A/G plus-agarose (Santa Cruz Biotechnology) and gently shaken. The precipitates were washed thrice with ice-cold lysis buffer and resolved by SDS-PAGE followed by Western blot analysis.

**Cell viability assay.** CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega, Madison, WI) was used to evaluate cytotoxicity in LK2 stable transfectants. One hundred microliters of an exponentially growing cell suspension (3–5  $\times$  10<sup>3</sup> cells) was seeded into a 96-well plate. The following day, various concentrations of gefitinib were added. After incubation for 72 hours at 37°C, 100  $\mu$ L of CellTiter-Glo Reagent were added to each well and the plates were shaken gently for 2 minutes. After incubation for 10 minutes at room temperature, luminescence was measured using a multilabel counter (Wallac, Tokyo, Japan) (23, 36). Each experiment was done using three replicate wells for each drug concentration.


**Colony formation assay.** Cell survival was determined by plating 3 to 9  $\times$  10<sup>2</sup> cells in 35-mm dishes. After 24 hours, various concentrations of gefitinib were added, followed by incubation for 7 to 10 days at 37°C. Gefitinib was solubilized in DMSO. Control experiments were done by adding equivalent volumes of DMSO to plates. Colonies were counted after Giemsa staining as described previously (23).

**Fluorescence-activated cell sorting analysis.** The cells were seeded in a 6-cm dish and allowed to grow overnight. Gefitinib (1 or 5  $\mu$ mol/L) was added for 48 hours at 37°C and cells were then fixed overnight in ethanol at 4°C. Fixed cells were resuspended in a propidium iodide solution (15  $\mu$ g/mL) containing RNase A (50  $\mu$ g/mL) before incubation at room temperature for 1 hour. Cell cycle analysis was done using FACScan and Cell Quest software (Becton Dickinson Labware, Mountain View, CA).

## Results

**Overexpression of HER2 increases sensitivity to gefitinib in LK2 cells.** First, we asked whether HER2 overexpression affects sensitivity to gefitinib by examining LK2/parent cells, LK2/mock cells, and HER2 cDNA transfectants. Two HER2 transfectants (LK2/HER2-32 and LK2/HER2-57) were isolated after introduction of human HER2 cDNA into LK2 cells expressing moderate levels of HER3, and very low levels of EGFR and HER2. These HER2 transfectants showed much higher HER2 expression than their parental counterparts, LK2 cells, and LK2/mock cells (Fig. 1A). We observed no apparent differences in the growth rates between LK2/mock and its two HER2 transfectants under exponential growth conditions in the absence or presence of EGF (Fig. 1B).

The expression levels of HER3 were similar among the four cell lines. Both LK2/HER2-32 and LK2/HER2-57 cells showed an approximately 2-fold greater sensitivity to the cytotoxic effects of gefitinib than their parental counterparts, when  $IC_{50}$  values were determined by cell survival assay (Fig. 2A). Both HER2 transfectants showed similar sensitivities to gefitinib when assayed by cell survival assay. A separate assay, which was assessed by colony formation, showed LK2/HER2-57 cells to be approximately 5-fold more sensitive to gefitinib than LK2/mock cells and QG56 cells (Fig. 2B). However, sensitivity was about 20-fold lower in LK2/HER2-57 cells than in PC9 cells, which harbor in-frame deletion mutation of EGFR (E746-A750) in exon 19 (23). Our previous



**Figure 1.** Overexpression of HER2 does not alter growth rate with or without EGF. *A*, comparison of HER2, HER3, and p85 $\alpha$  protein expression levels in LK2, LK2/mock, and its two HER2 transfectants. Protein extracts were resolved by 7.5% SDS-PAGE and probed with each antibody. Immunoreactive proteins were visualized by enhanced chemiluminescence. *B*, cell growth rates are evaluated in LK2 and its HER2 transfectants under normal growth conditions with or without 20 ng/mL of EGF. Cells were harvested by trypsinization and counted by a Coulter counter at the indicated time intervals after seeding. Columns, mean value of three dishes, and each value is within the range of 10% error.

research has shown that among nine NSCLC cell lines tested, PC9 is the most sensitive to gefitinib, and QG56 and LK2 are the most resistant (23). Thus, overexpression of HER2 seems to alter the sensitivity of LK2 cells to gefitinib.


The presence or absence of EGFR mutations plays a key role in the drug sensitivity of NSCLC cells to gefitinib (21, 22). We examined the absence or presence of any mutation in exons 18, 19, and 21 of EGFR gene, and found no mutation in LK2, LK2/mock, two HER2 transfectants and QG56 (data not shown).

**Gefitinib inhibits Akt phosphorylation in a dose-dependent manner in LK2/HER2 cells.** HER2 activates a number of cytoplasmic signal transduction pathways including the PI3K/Akt pathway and the Ras/MAP kinase pathway. We compared the effects of gefitinib on phosphorylation of HER2, Akt, and ERK1/2 in four cell lines: LK2/parent, LK2/mock, LK2/HER2-32, and LK2/HER2-57. Figure 3A shows the effects of gefitinib on phosphorylation of HER2, Akt, and ERK1/2 in these cell lines under basal growth conditions in the presence of 10% serum. In all four cell lines, HER2, Akt, and ERK1/2 were phosphorylated in the absence of the drug, although HER2 phosphorylation levels in LK2/parent and LK2/mock cells were much lower than that in LK2/HER2 cell lines. P-Akt was found to be 1.9- and 1.7-fold higher in LK2/HER2-32 and LK2/HER2-57, respectively, than in LK2/mock in the

absence of drug (Fig. 3A). Moreover, P-ERK1/2 in both LK2/HER2-32 and LK2/HER2-57 was about 1.3-fold higher than that in LK2/mock in the absence of drug.

Figure 3B shows inhibition dose kinetics of gefitinib for Akt and ERK1/2 in these cells, with the phosphorylation activity of these targets without gefitinib normalized as 100%. In LK2/parent cells and LK2/mock cells, activation of both Akt and ERK1/2 was not changed by gefitinib up to 10  $\mu$ M/L (Fig. 3A and B). However, in the two LK2/HER2 cell lines, Akt activation was inhibited by gefitinib in a dose-dependent manner, being blocked at 50% control on application of 1  $\mu$ M/L gefitinib. Application of 5 to 10  $\mu$ M/L gefitinib reduced HER2 phosphorylation by 40% to 60% of the activity in the absence of drug, whereas gefitinib did not show any inhibitory effect on ERK1/2 activation (Fig. 3A and B). Overexpression of HER2 thus enhanced drug sensitivity to gefitinib in LK2 cells and also specifically sensitized the gefitinib-induced inhibition of PI3K/Akt pathway.

**Gefitinib arrests the cell cycle at G<sub>1</sub> and increases p27<sup>Kip1</sup> expression levels in LK2/HER2 cells.** To examine whether the inhibitory effects observed in cell growth assays reflect a delay or arrest of cell cycle in the G<sub>0</sub>/G<sub>1</sub> phase, as shown previously (37–39), cells were treated with gefitinib for 48 hours, and cell cycle progression was evaluated by fluorescence-activated cell sorting




**Figure 2.** Overexpression of HER2 increases sensitivity to gefitinib in LK2. *A*, dose-response curves of the parental LK2, LK2/mock, and two HER2 transfectants. Drug sensitivity was determined using a cell viability assay in the absence or presence of different doses of gefitinib. The number of viable cells was calculated at 72 hours and graphed as the percentage of untreated cells. Each value is the average of triplicate dishes (SD). *B*, dose-response curves of two NSCLC cell lines (PC9, gefitinib-sensitive cell line; and QG56, gefitinib-insensitive cell line), LK2/HER2 and LK2/mock. Cell survival was determined by colony formation assay in the absence or presence of various doses of gefitinib. The number of colonies after incubation for 7 days with or without gefitinib was presented as a percentage of untreated cells.


analysis. Treatment with gefitinib increased the portion of cells in G<sub>0</sub>/G<sub>1</sub> phase by 7% to 8% in the two LK2/HER2 cell lines, with a corresponding decrease in the portion of cells in S and G<sub>2</sub>-M phases (Fig. 4A and B). In contrast, in LK2/mock cells, no change in cell cycle distribution was detected upon treatment with gefitinib. Furthermore, no sub-G<sub>1</sub> fraction, indicative of apoptosis, was observed following gefitinib treatment in any of the cell lines. We subsequently examined the effects of gefitinib on p27<sup>Kip1</sup> and p21<sup>WAF1/CIP1</sup> expression, because both of them have been implicated in the growth arrest after disruption of EGFR tyrosine kinase activity in EGFR or HER2 overexpressing cells (refs. 40, 41; Fig. 4C). In all cell lines, only a small amount of p27<sup>Kip1</sup> was expressed in the absence of the drug. Treatment with gefitinib (5 μmol/L) led to an increase in p27<sup>Kip1</sup> levels: approximately 8-fold in LK2/HER2-32 cells, and 4- to 5-fold in LK2/HER2-57 cells, when there was only a slight if any change in the p27<sup>Kip1</sup> levels in LK2/mock cells. In contrast, p21<sup>WAF1/CIP1</sup> expression was unchanged in all of the clones after gefitinib treatment. Although inhibition by gefitinib in both growth curves and Akt activation was similar between LK2/HER2-32 and LK2/HER2-57, a slight but reproducible

difference in an increase of p27<sup>Kip1</sup> was observed between the two gefitinib-treated transfectants. However, the underlying mechanism of why this difference in p27<sup>Kip1</sup> expression levels by gefitinib appears remains to be further studied.

**Gefitinib inhibits constitutive association of HER3 with HER2 as well as p85α, and basal HER3 phosphorylation in LK2/HER2 cells.** LK2 cells expressed no detectable levels of EGFR, but sufficient levels of HER3 (23). HER3 efficiently recruits p85α, but HER2 lacks the appropriate binding site(s) for this (42, 43). Moreover, the constitutive association of HER2/HER3 is often observed in tumor cells overexpressing HER2 (44). We examined the effect of gefitinib on the association of HER2 with HER3, and that of HER3 with p85α. LK2/HER2 and LK2/mock cells were treated with gefitinib for 3 hours and then cell lysates were immunoprecipitated with anti-HER3 antibodies, followed by Western blot analysis (Fig. 5). HER3 was coprecipitated with HER2 in LK2/HER2-32 and LK2/HER2-57 cells under basal growth conditions, indicating the presence of constitutive HER2/HER3 complexes. In LK2/mock cells, no HER2/HER3 heterodimer formation was apparent and HER3 exhibited only slight, if any, tyrosine phosphorylation and almost no



**Figure 3.** Gefitinib inhibits Akt phosphorylation in a dose-dependent manner in LK2/HER2. *A*, exponentially growing cells in 10% serum medium were pretreated for 3 hours with the indicated concentrations of gefitinib. Protein extracts were resolved by 7.5% SDS-PAGE and probed with antibodies. HER2, Akt, and ERK1/2 activity was determined using each corresponding anti-phospho antibody. Relative levels of P-Akt and P-ERK1/2 in LK2/HER2-32 and LK2/HER2-57 are presented when basal phosphoprotein levels of each Akt and ERK1/2 in LK2/mock is presented as 100%. *B*, quantitative analysis of Akt and ERK1/2 activity was done on the immunoblots using Image Gauge V3.45 software and plotted for each cell line using the 0 μmol/L arm as a control.



**Figure 4.** Gefitinib increases the proportion of cells in the  $G_0/G_1$  phase of the cell cycle and increases p27<sup>Kip1</sup> expression levels in LK2/HER2. **A**, cell cycle profiles of LK2/HER2 and LK2/mock at 48 hours after treatment with or without gefitinib are presented. Cell cycle distribution was determined by curve-fitting using the ModFit LT software. **B**, the result of cell cycle analysis of LK2/HER2 and LK2/mock. The mean values (SD) for each phase of the cell cycle are shown on the graph and in the table. **C**, exponentially growing cells were pretreated for 48 hours with the indicated concentrations of gefitinib. Protein extracts were resolved by 7.5% SDS-PAGE and probed with either antibody.

association with p85 $\alpha$ . In contrast, in LK2/HER2 cell lines, HER3 exhibited a high level of basal tyrosine phosphorylation and association with p85 $\alpha$ . Treatment with gefitinib markedly abrogated HER3 phosphorylation as well as the association of HER3 with HER2, and HER3 with p85 $\alpha$ .

## Discussion

In a recent study, we examined the molecular basis of sensitivity to gefitinib using nine NSCLC cell lines, and we found that PC9 was

most sensitive to the drug. These nine cell lines expressed different levels of EGFR, HER2, HER3, and HER4, but there appeared to be no correlation between EGFR and/or HER2 expression and drug sensitivity (23). However, the activation of EGFR, Akt and ERK1/2 was inhibited by much lower concentrations of gefitinib in PC9 cells than in the other eight cell lines under basal growth conditions. This suggests that sensitivity to growth inhibition by gefitinib in NSCLC cell lines is dependent upon the activation levels of Akt and ERK1/2 in response to EGFR signaling for survival and


proliferation (23). Moreover, two established EGFR cDNA transfectants (LK2/EGFR-2 and LK2/EGFR-5) were found to show a similar level of sensitivity to gefitinib in the parental strain (23). In this study, overexpression of HER2 in LK2 cells is shown to result in enhanced drug sensitivity to gefitinib (Fig. 2A and B). Thus, the expression of HER2, but not EGFR, seems to modulate drug sensitivity to gefitinib in this NSCLC cell line. Therapeutic efficacy of gefitinib against NSCLC was found to be closely associated with somatic mutations in the EGFR kinase domain (21, 22), and we found that one highly gefitinib-sensitive NSCLC cell line, PC9, also has a deletion mutation (E746-A750) in exon 19 of EGFR catalytic domain. LK2, LK2/mock, and its two HER2 transfectants, had no such mutations in exon 18, 19, and 21 of the EGFR catalytic domain, suggesting that HER2 overexpression did not induce EGFR mutation in LK2 cells.

In HER2-transfected LK2 cells under basal growth conditions, application of 0.5 to 1  $\mu\text{mol/L}$  gefitinib specifically inhibited Akt activation, but not ERK1/2 activation. Treatment with gefitinib induced  $G_0/G_1$  arrest as well as the accumulation of  $p27^{\text{kip1}}$  but not of  $p21^{\text{WAF1/CIP1}}$ . The expression of CDK inhibitors,  $p27^{\text{kip1}}$  and  $p21^{\text{WAF1/CIP1}}$ , inhibits formation of the cyclin-CDK complexes essential for  $G_1$  to S phase progression (45). Inhibition of the EGFR-mediated pathway often induces up-regulation of both  $p27^{\text{kip1}}$  and  $p21^{\text{WAF1/CIP1}}$  (40, 41). In our present study, treatment with gefitinib of two HER2 transfectants resulted in no increase in  $p21^{\text{WAF1/CIP1}}$  expression but in up-regulation of  $p27^{\text{kip1}}$  consistent with recent study by Kalish et al. (46). They have shown the down-regulation of cyclin D1 expression by gefitinib with concomitant accumulation of  $p27^{\text{kip1}}$ , but no change in the expression level of  $p21^{\text{WAF1/CIP1}}$ . Accumulation of  $p27^{\text{kip1}}$  protein rather than  $p21^{\text{WAF1/CIP1}}$  protein seems to be specifically associated with growth arrest by gefitinib in LK2/HER2 transfectants.

Constitutive formation of HER2/HER3 heterodimers, and association of  $p85\alpha$  with HER3 were observed, and gefitinib at 1 to 5  $\mu\text{mol/L}$  markedly abrogated these associations. Taken together, overexpression of HER2 seems to sensitize LK2 cells to gefitinib, plausibly coordinated with HER3. A relevant study by Campiglio et al. (47) examined the effect of gefitinib on proliferation and survival, and its activation of Akt and ERK1/2, in six human breast cancer cell lines expressing various levels of


EGFR and HER2. This study reported that the effects of gefitinib are independent of EGFR expression levels, but are influenced by high HER2 expression (47). Moreover, recent studies have also reported that gefitinib has a good antitumor effect on tumors displaying higher HER2 levels (24–26). These studies, including our present study, consistently suggest that high HER2 expression confers increased sensitivity to the therapeutic effect of gefitinib. Gefitinib intrinsically shows very high affinity against EGFR, but about 100-fold less affinity against HER2 than EGFR (11).  $IC_{50}$  of gefitinib for EGFR phosphorylation was about 0.1 to 0.5  $\mu\text{mol/L}$  in various NSCLC lines (23), whereas  $IC_{50}$  of gefitinib for HER2 phosphorylation in LK2/HER2-32 and LK2/HER2-57 were about 10  $\mu\text{mol/L}$  (Fig. 3). In contrast, gefitinib inhibited HER3 phosphorylation in the heterodimer HER2/HER3 at  $IC_{50}$  of about 1  $\mu\text{mol/L}$  (Fig. 5), suggesting that HER3 is activated in the heterodimer with HER2, resulting in increased drug sensitivity to the inhibitory effect of gefitinib.

Overexpression of HER2 in LK2 cells resulted in a marked inhibitory effect of gefitinib on Akt phosphorylation, but not on ERK1/2 phosphorylation. HER2 phosphorylation under exponential growth conditions was moderately affected when gefitinib was used at high concentrations. Ras/ERK1/2 signaling is associated with cell proliferation, and Akt signaling is associated with cell survival (3, 48). Thus, HER2 seems to operate through Akt signaling, coordinated with HER3 and  $p85\alpha$  in LK2/HER2 cells (see Fig. 6), and this signaling might be specifically affected by gefitinib. On the other hand, EGFR tyrosine kinase inhibitors often disrupt the formation of HER2/HER3 heterodimers in HER2-overexpressing cancer cells (25, 27), and we have shown that association of HER2 with HER3 in LK2/HER2 cells is markedly abrogated by gefitinib (Fig. 5). Expression of HER2 is essential for the dimer formation of HER2 and HER3, whereas exogenous addition of heregulin, a specific ligand for HER3, could not further enhance dimer formation or HER3 phosphorylation, in LK2/HER2 transfectants (data not shown). Treatment with gefitinib inhibited HER3 phosphorylation with release of  $p85\alpha$  in LK2/HER2 cells under basal growth conditions. Concomitant disruption of HER2/HER3 formation by gefitinib, and the associated release of  $p85\alpha$ , seems to specifically affect Akt signaling, resulting in growth arrest of cancer cells (Fig. 6).



**Figure 5.** Gefitinib inhibits the formation of HER2/HER3 heterodimers and the association of HER3 with  $p85\alpha$  in LK2/HER2 cells. Exponentially growing LK2/HER2 or LK2/mock in 10% serum medium were treated with gefitinib (0.1 or 5  $\mu\text{mol/L}$ ) for 3 hours. After cell lysis, HER3 was immunoprecipitated with specific antibody. The immunoprecipitates were divided equally and subjected to immunoblot analysis using the indicated antibodies against HER3, P-Tyr, HER2, and  $p85\alpha$ , respectively.

**Figure 6.** A hypothetical model of how drug sensitivity to gefitinib is controlled in HER2 expressing NSCLC cells. In gefitinib-resistant cell lines (LK2/mock and LK2/parent) with no significant expression of EGFR, EGFR is not a survival factor for these cells. Cell proliferation and apoptosis are expected to be driven by other growth factor receptors that might not be targets for gefitinib. On the other hand, in gefitinib-sensitive cell lines (LK2/HER2-32 and LK2/HER2-57), only HER2-driven signaling was dominant, following activation of Akt through the formation of heterodimers with HER3. Therefore, cell survival and death, both of which are dependent on HER2/HER3 signaling, are highly susceptible to gefitinib.



In conclusion a NSCLC cell line, LK2, has no apparent expression of EGFR and HER2, but expresses HER3 moderately, suggesting that HER2 (this study) as well as EGFR (23) does not seem to act as survival factors in LK2 cells. Cell proliferation and apoptosis in LK2 cells are expected to be driven by other growth factor receptors that are not targets for gefitinib (Fig. 6A). Overexpression of EGFR in LK2 cells resulted in no altered drug sensitivity to gefitinib (23). In contrast, overexpression of HER2 in LK2 cells results in enhanced drug sensitivity to gefitinib, and stimulates HER2-driven signaling accompanied by activation of Akt, plausibly through HER2/HER3 heterodimer formation (Fig. 6B). Cell survival and death, which are dependent on HER2/HER3 signaling, are then expected to be highly responsive to gefitinib treatment. Although our present study was done with artificially gene-modified cancer cells through wild-type HER2 cDNA transfection, Moasser et al. (24) have previously reported that gefitinib selectively inhibits HER2-

driven signaling and suppress the growth of HER2-overexpressing breast and ovary cancer cell lines: these cancer cell lines were established from cancer patients without gene transfection. Further assessment of the activation levels of HER2 and/or HER3 could be useful in determining the therapeutic efficacy of the drug in a subgroup of NSCLC patients.

## Acknowledgments

Received 8/2/2004; revised 12/26/2004; accepted 2/9/2005.

**Grant support:** Grant-in-aid for cancer research from the Ministry of Education, Science and Culture, Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Tadashi Yamamoto (Tokyo University) for supplying the HER2 vector, Dr. Yukito Ichinose for supplying cancer cell lines and fruitful discussion; and Tomoko Tsurusaki and Naomi Shinbaru for their editorial help.

## References

- Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. *Cell* 1991;64:271-80.
- Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. *EMBO J* 2000;19:3159-67.
- Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. *Endocr Relat Cancer* 2001;8:11-31.
- Iihara K, Shiozaki H, Tahara H, et al. Prognostic significance of transforming growth factor- $\alpha$  in human esophageal carcinoma. Implication for the autocrine proliferation. *Cancer* 1993;71:2902-9.
- Hu G, Liu W, Mendelsohn J, et al. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. *J Natl Cancer Inst* 1997;89:1271-6.
- Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF- $\alpha$  and EGFR protein in head and neck squamous cell carcinoma and patient survival. *J Natl Cancer Inst* 1998;90:824-32.
- Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. *Cancer Treat Rev* 2004;30:1-17.
- Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. *Oncogene* 2000;19:6550-65.
- Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. *Drugs* 2000;60:25-32; discussion 41-2.
- Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. *J Clin Oncol* 2002;20:2217-9.
- Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. *Pharmacol Ther* 1999;82:241-50.
- Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. *J Clin Oncol* 2002;20:110-24.
- Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. *Clin Cancer Res* 2000;6:2053-63.
- Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. *Clin Cancer Res* 2000;6:4885-92.

15. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer patients who had failed platinum and docetaxel-based regimens (IDEAL 2). *Proc Am Soc Clin Oncol* 2002;21:292a.
16. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2003;21:2237-46.
17. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. *J Clin Oncol* 2002;20:2240-50.
18. Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). *Clin Cancer Res* 2000;8:3250-8.
19. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 (Iressa), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. *Br J Cancer* 2002;86:1157-61.
20. She Y, Lee F, Chen J, Haimovitz-Friedman A, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. *Clin Cancer Res* 2003;9:3773-8.
21. Lynch TJ, Bell DW, Sordelia R, Gurubhagavanda S, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell-lung cancer to gefitinib. *N Engl J Med* 2004;350:2129-39.
22. Paez JG, Jänne PA, Lee JC, Tracy S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497-500.
23. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib ('Iressa', ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extra cellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. *Mol Cancer Ther* 2004;3:465-72.
24. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. *Cancer Res* 2001;61:7184-8.
25. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells *in vitro* and *in vivo*. *Cancer Res* 2001;61:8887-95.
26. Normanno N, Campiglio M, De LA, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. *Ann Oncol* 2002;13:65-72.
27. Anido J, Matar P, Albanell J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. *Clin Cancer Res* 2003;9:1274-83.
28. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. *Science* 1986;232:1644-6.
29. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 1989;244:707-12.
30. Schraml P, Kononen J, Bubendorf L, Moch H, et al. Tissue microarrays for gene amplification surveys in many different tumor types. *Clin Cancer Res* 1999;5:1966-75.
31. Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF, HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. *Semin Oncol* 2000;27:53-63; discussion 92-100.
32. Nakamura H, Saji H, Ogata A, et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. *Int J Cancer* 2003;103:61-6.
33. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987;235:177-82.
34. Fajac A, Benard J, Lhomme C, et al. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. *Int J Cancer* 1995;64:146-51.
35. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. *Oncogene* 2003;22:6570-8.
36. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. *Cancer Res* 2002;62:2554-60.
37. Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. *Cancer Res* 2002;62:5242-7.
38. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. *Clin Cancer Res* 2003;9:2316-26.
39. Shintani S, Li C, Mihara M, et al. Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G<sub>1</sub> arrest in oral squamous cell carcinoma cell lines. *Oral Oncol* 2004;40:43-51.
40. Lenferink AE, Busse D, Flanagan WM, et al. ErbB2/neu kinase modulates cellular p27 (Kip1) and cyclin D1 through multiple signaling pathways. *Cancer Res* 2001;61:6583-91.
41. Di Gennaro E, Barbarino M, Bruzzese F, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. *J Cell Physiol* 2004;195:139-50.
42. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. *EMBO J* 1994;13:2831-41.
43. Soltoff SP, Carraway KL III, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. *Mol Cell Biol* 1994;14:3550-8.
44. Alimandi M, Romano A, Curia MC, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. *Oncogene* 1995;10:1813-21.
45. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G<sub>1</sub>-phase progression. *Genes Dev* 1999;13:1501-12.
46. Kalish LH, Kwong RA, Cole IE, et al. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. *Clin Cancer Res* 2004;15:7764-74.
47. Campiglio M, Locatelli A, Olgiati C, et al. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression. *J Cell Physiol* 2004;198:259-68.
48. Gamett DC, Pearson G, Cerione RA, Friedberg I. Secondary dimerization between members of the epidermal growth factor receptor family. *J Biol Chem* 1997;272:12052-6.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells

Akira Hirata, Fumihito Hosoi, Miho Miyagawa, et al.

*Cancer Res* 2005;65:4253-4260.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/65/10/4253>

**Cited articles** This article cites 48 articles, 25 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/65/10/4253.full#ref-list-1>

**Citing articles** This article has been cited by 19 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/65/10/4253.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/65/10/4253>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.